Articles tagged with Cervical Cancer
Researchers at Albert Einstein College of Medicine found that genetic differences in a gene called TAP can provide protection against high-grade Cervical Neoplasia, which is a premalignant condition caused by HPV.
A study by Massachusetts General Hospital found that both Latino and non-Latino women are more likely to accept HPV vaccination for themselves and their children than previously reported. The main motivator for these women is the prevention of cancer, with no association between vaccine acceptance and income or education level.
A study found that pretreatment MRI and PET/CT can direct women with stage IB cervical cancer to optimal therapy choices, avoiding trimodality therapy. The imaging modalities resulted in the highest percentage of correct primary treatment (89%) and saved the most patients from trimodality therapy (95%).
A new study published in BMC Public Health found that cervical cancer incidence varies among geographical areas in Southeast England, with higher rates in more deprived areas. The research analyzed data on 2,231 cases of cervical cancer diagnosed between 2001 and 2005, revealing dramatic variations within regions.
A study published in the Journal of the National Cancer Institute found that HPV18 DNA levels are not associated with the likelihood of progressing to advanced precancerous lesions of the cervix. The study suggests that testing for high levels of HPV18 DNA is not clinically useful.
Denise Galloway, a microbiologist, was honored for her work on human papillomaviruses causing anogenital malignancies. Her studies established that nearly all cervical cancers are caused by HPVs, leading to breakthroughs in Gardasil vaccine development. Gerald Smith, a geneticist and microbiologist, was recognized for his research on h...
New studies suggest that male circumcision can lower the risk of human papillomavirus (HPV) infection, particularly high-risk subtypes associated with cervical, penile, and other cancers. Circumcised men are about half as likely to have HPV as uncircumcised men, according to research published in The Journal of Infectious Diseases.
Arbor Vita Corporation presented new data on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer detection. The test detects the E6 oncoprotein produced by human papillomavirus (HPV), which is a diagnostic marker of high positive predictive value.
A comprehensive assessment of HPV-associated cancers found significant racial disparities, with higher rates among African American women and Hispanic men. The study also identified the most common types of HPV-related cancers, including cervical, anal, and oral cancers.
The HPV-positive cancer cells adapted to the hypoxic environment by expressing a protein that activates a cell signaling pathway, helping them survive, grow and spread. The study may lead to new therapies targeting this pathway to interrupt cancer cell proliferation.
Researchers have developed a new MRI technique that can identify cervical cancer in its early stages by measuring the movement of water within tissue. The technique offers better imaging of smaller tumors and may improve surgical options for fertility-sparing procedures.
Only about half of Medicaid recipients aged 50 and older receive recommended cancer screenings for colorectal, breast, and cervical cancer. Despite access to primary care and full coverage, these rates are significantly lower than those in the general population.
A computer model analysis suggests that different cervical cancer prevention approaches offer varying trade-offs between minimizing cancer risk and false-positive test results. Combined cytologic and HPV testing leads to more referrals for colposcopy than other strategies, with a three-fold difference in referrals for the least and mos...
A new rapid screening test for HPV has shown a 90% success rate in detecting precancerous cervical disease in rural China. The careHPV test is designed to be simple, affordable, and easy to perform with minimal training, offering hope for cervical cancer prevention in low-resource settings.
The careHPV test provides substantially more accurate front-line screening than current methods in developing countries. It has a sensitivity of 90% and can be conducted by workers with minimal healthcare training, making it accessible to under-served regions.
A new rapid screening test for HPV has shown a 90% success rate in detecting precancerous cells in women in Shanxi province, eastern China. The careHPV test is designed to be simple, affordable and easy to use, making it an effective primary screening method for cervical-cancer prevention in rural and low-resource settings.
Researchers found that HPV testing with P16INK4A expression increases sensitivity for detecting high-grade precancerous cervical lesions compared to conventional cytology. This improvement comes without increasing referral to colposcopy. The study suggests using triage by P16INK4A immunostaining in HPV-positive women.
A new study by Karolinska Institutet found that immigrant women from different countries have varying risks of developing cervical cancer. Women from east Africa had a significantly lower risk, while those from Norway and Denmark had a higher risk.
The World Cancer Declaration aims to tackle the growing cancer crisis in developing countries with 11 cancer-busting targets for 2020. The plan focuses on significant drops in tobacco consumption, obesity and alcohol intake, as well as universal vaccination programs and proper pain medication.
Cervical cancer control is becoming feasible in developing countries due to highly effective vaccines and promising new screening tests. The monograph presents the best global thinking on cervical cancer prevention with vaccination and screening, evaluating cost-effectiveness and affordability.
The study suggests that universal vaccine coverage in young adolescent girls, initial catch-up efforts for women under 21, and revised screening policies can significantly reduce cervical cancer rates. Vaccination is predicted to be economically attractive if achieved in 12-year-old girls with long-lasting protection.
A University of Alberta study found that obese Canadian women are 30-40% less likely to receive recommended cervical cancer screening, with fear of pain or embarrassment cited as a reason for non-screening. In contrast, breast and colon cancer screening rates remained unchanged.
A study published in PLOS Medicine found that only 19% of women in the developing world have been screened effectively for cervical cancer. The study reveals significant inequalities in access to screening services between and within countries.
Research by Professor Jillian Birch found that cancer incidence and mortality rates decrease with increasing deprivation among teenagers and young adults. Notably, cervical cancer and melanoma show increasing rates despite being preventable.
A UNC study found a consistent association between six-month to one-year persistent HPV infections and high-grade cervical lesions or cervical cancer. The study suggests that measuring HPV persistence could optimize screening for cervical cancer by increasing sensitivity while maintaining specificity.
A recent study found that US mothers are less likely to vaccinate their youngest daughters against human papillomavirus virus (HPV), even though the vaccine is recommended for girls aged 11 and 12. The researchers identified key factors associated with intention to vaccinate, including beliefs about HPV vaccination and perceived benefits.
A nationwide study found that regular cervical cancer screening reduces incidence rates in all ages, particularly among younger women. However, imperfect population coverage and inadequate follow-up programs remain major risk factors, highlighting the need for improved screening programs.
A UC Irvine study found that phone counseling improved quality of life and immune systems in cervical cancer survivors, with improved anti-tumor immune responses. The 'mind-body' connection plays a crucial role in surviving cancer with a higher quality of life.
A new study shows that MRI and PET/CT can triage patients with stage 1B cervical cancer to optimal first-line therapy, preventing unnecessary trimodality therapy. The combination of both imaging modalities results in a 95% reduction in patients being triaged to high-morbidity treatment.
A study examined 75 group-randomized oncology trials and found a substantial number of problems with the trials. Many relied on analyses that ignored group randomization altogether, raising concerns about type I errors. In contrast, HPV-based screening was found to be more accurate in detecting cervical precancerous lesions than cytology.
A team of researchers from the University of Leeds has identified a critical weakness in Human Papillomavirus (HPV) that may lead to new treatments for cervical cancer. The E7 protein helps HPV evade the immune system, but it also makes infected cells vulnerable to attack by Natural Killer cells.
Zur Hausen demonstrated the role of human papillomavirus in cervical cancer, providing key findings that led to the recognition of HPV as a primary cause. His research also linked HPV to other cancers, including laryngeal carcinoma and penile carcinoma.
A large randomized trial of personalized interventions found that two behavioral interventions did not significantly increase regular mammograms in female veterans. The study's findings support the generalizability to the US female population, which has seen a decline in mammography rates. Meanwhile, another study suggests that viral D...
A new study finds that women with higher levels of perceived stress are more likely to have an impaired immune response to HPV16, increasing their risk of developing cervical cancer. Most HPV infections in healthy women will disappear spontaneously over time.
Researchers investigated how cell signaling in the stroma of cervical cancer affects tumor growth, revealing a key role for platelet-derived growth factor (PDGF). A genetic variant impairing glycogen synthesis was also identified in human skeletal muscles and linked to decreased muscle glycogen content.
A new study estimated the costs of providing comprehensive screening and diagnostic services to under- or uninsured, low-income women. The median cost of screening a woman for breast cancer was $94, while the cost per detected case was $10,566. For cervical cancer, these costs were $56 and $13,340, respectively.
A study by Dr. Groesbeck Parham found that 90% of HIV-infected women presenting for antiretroviral therapy harbor cervical cell abnormalities, increasing the risk of cervical cancer. Access to screening and treatment is crucial to prevent this life-threatening condition in women living with AIDS.
Post-treatment PET scans can accurately detect cervical cancer tumor response and predict long-term survival. The scans help identify patients whose tumors have not responded to therapy, allowing for alternative treatment options.
Current oral contraceptive users have a higher risk of developing cervical cancer, but this risk returns to normal after 10 years of not using the contraceptives. The study also found that women who test positive for high-risk human papillomavirus are more likely to develop in-situ or invasive cervical cancer.
The Seneca Valley Virus shows promise as a treatment for some metastatic cancers. Cervical cancer survivors are at greater risk of second cancers due to radiation exposure. A novel trial design identifies promising treatments in clinical trials.
A new study from McGill University finds that the HPV screening test outperforms the traditional Pap test in detecting pre-cancerous lesions without false negatives. The HPV test achieved an accuracy of 94.6%, while the Pap test only reached 55.4% accuracy, making it a more reliable method for cervical cancer screening.
The Phase I/II trial tested Lovaxin C in stage IVb cervical cancer patients, with symptoms including flu-like syndrome, fever, chills, nausea, and vomiting. The study found that five patients experienced tumor reductions or complete disappearance of tumors, while seven patients remained stable, and one patient achieved a partial response.
A new study found that HPV DNA testing can detect clinically relevant cervical lesions earlier than conventional cytological techniques. This allows for the potential extension of the screening interval by at least one year. Earlier detection reduces the lifetime number of screening tests and referrals, benefiting women.
A recent study has found that couples are more likely to divorce if one of their spouses develops cervical or testicular cancer. Most types of cancer resulted in a slight decrease in the divorce rate in the first few years following the diagnosis.
A study found that the -765G>C COX2 polymorphism increases the risk of ovarian cancer by nearly two-fold in C allele carriers and nearly three-fold in women under 53. The mutation may enhance COX-2 gene expression, inhibiting apoptosis and promoting tumour proliferation.
A new study found that irregular Pap smears and false negative tests were not the primary reasons for cervical cancer development. Instead, socio-economic disparities in screening access may be a major obstacle to eradicating the disease.
Researchers found that cervical tumors with high glucose uptake (SUV) on PET scans had higher recurrence rates, persistent disease, and lower survival rates. The study suggests that SUV is a more sensitive indicator of tumor aggressiveness than standard staging protocols.
Existing technology and resources can solve cervical cancer's global burden, especially in developing countries. The disease disproportionately affects women worldwide, particularly in regions with limited resources.
A research letter investigates the feasibility of self-collected HPV specimens for testing among women at high risk of cervical cancer. The study found that outreach nurses were able to recontact 81.4% of participants who tested positive and referred them for further testing.
A study published in JAMA found that the HPV-16/18 vaccine does not accelerate clearance of the virus in women with pre-existing infections. The vaccine is effective only in preventing new HPV infections and cervical precancers.
A simple visual inspection technique using acetic acid (VIA) has been shown to reduce cervical cancer incidence in poor countries by up to 35%. The study found that VIA screening led to a significant decrease in cervical cancer cases and deaths among women in the intervention group compared to those in the control group.
A study from the University of North Carolina at Chapel Hill found that HPV types 16 and 18 are responsible for 70% of invasive cervical cancer cases globally. The researchers analyzed data on over 14,000 invasive and high-grade cases to estimate the prevalence of different virus types.
A landmark study finds that HIV/AIDS patients are 11 times more likely to develop Hodgkin's lymphoma, while transplant recipients face a similar increased risk for several types of cancer. Immune deficiency is the common factor driving these higher cancer rates in both groups.
The Cervarix vaccine demonstrates effective protection against high-grade cervical pre-cancerous lesions caused by HPV types 16 and 18, and also provides additional protection against other strains of HPV that account for 10% of cervical cancers. The study involved over 18,000 women aged 15-25 years from around the world and found the ...
Recent studies found a decline in Kaposi sarcoma and non-Hodgkin lymphoma incidence among AIDS patients treated with HAART, associated with increased CD4 cell counts. Additionally, researchers identified the CCRK gene as potentially involved in glioblastoma multiforme development.
The quadrivalent HPV vaccine has been shown to be highly effective in preventing cervical cancer and precancerous lesions. The study found that the vaccine was 99% effective in women who had never had sex, but efficacy decreased to 44% when data from women who could have been exposed was included.
International studies show high efficacy for HPV vaccine. The vaccine is highly effective in preventing pre-malignant changes of the cervix and protects against serious HPV-related diseases, including high-grade cervical pre-cancers.
A new HPV vaccine has shown near 100 percent efficacy in preventing the two types of human papillomavirus responsible for most cases of cervical cancer. The vaccine targets HPV types 16 and 18, causing about 70 percent of all cases of cervical cancer.
A one-visit screening technique for cervical cancer shows safety, acceptability, and feasibility in Ghana. The single-visit procedure involves applying acetic acid to detect precancerous areas, followed by cryotherapy to eliminate abnormalities.
Researchers have discovered that antibody signals can activate leukocytes to promote cell growth and increase blood supply in precancerous tissues, fueling cancer progression. Potential drugs already being tested may be able to block this pathway, offering a new therapeutic strategy for treating B cell lymphoma and autoimmune diseases.